Daridorexant

Daridorexant
Clinical data
Other names	Nemorexant; ACT-541468
Routes of; administration	By mouth
Drug class	Orexin antagonist
Identifiers
	IUPAC name [(2S)-2-(5-Chloro-4-methyl-1H-benzimidazol-2-yl)-2-methylpyrrolidin-1-yl]-[5-methoxy-2-(triazol-2-yl)phenyl]methanone;
CAS Number	1505484-82-1;
PubChem CID	91801202;
ChemSpider	64854514;
UNII	LMQ24G57E9;
KEGG	D11886;
PDB ligand	NS2 (PDBe, RCSB PDB);
Chemical and physical data
Formula	C23H23ClN6O2
Molar mass	450.93 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=C(C=CC2=C1N=C(N2)[C@@]3(CCCN3C(=O)C4=C(C=CC(=C4)OC)N5N=CC=N5)C)Cl;
	InChI InChI=1S/C23H23ClN6O2/c1-14-17(24)6-7-18-20(14)28-22(27-18)23(2)9-4-12-29(23)21(31)16-13-15(32-3)5-8-19(16)30-25-10-11-26-30/h5-8,10-11,13H,4,9,12H2,1-3H3,(H,27,28)/t23-/m0/s1; Key:NBGABHGMJVIVBW-QHCPKHFHSA-N;

Daridorexant (developmental code name ACT-541468), formerly known as nemorexant, is a dual orexin receptor antagonist (DORA) which was originated by Actelion Pharmaceuticals and is under development by Idorsia Pharmaceuticals for the treatment of insomnia.[1][2] It acts as a selective dual antagonist of the orexin receptors OX₁ and OX₂.[1][2] As of April 2020, daridorexant has passed its first phase III clinical trial for the treatment of insomnia.[1]

References

"Daridorexant - Idorsia Pharmaceuticals - AdisInsight".
Equihua-Benítez AC, Guzmán-Vásquez K, Drucker-Colín R (July 2017). "Understanding sleep-wake mechanisms and drug discovery". Expert Opin Drug Discov. 12 (7): 643–657. doi:10.1080/17460441.2017.1329818. PMID 28511597.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.